GIC

GIC is the sovereign wealth fund of Singapore, one of the largest institutional investors globally with substantial healthcare exposure across pharmaceuticals, therapeutics, digital health, hospital networks, and life sciences infrastructure. GIC’s check sizes at the relevant stages are in the $25M-plus range, focused on Series C, Series D, and growth-stage opportunities, and the firm engages across global healthcare markets with a long-horizon institutional posture rather than a fund-cycle posture. The healthcare portfolio reflects a balance of late-stage venture, growth equity, and PE positions across the US, Europe, and Asia. The geographic focus is global, with the Singapore headquarters anchoring deep relationships across the Asian healthcare ecosystem and a US team active across major biotech and digital health hubs. The right founder profile is a CEO running a Series C or growth-stage healthcare business with proven commercial traction, institutional financial discipline, and a credible global expansion or strategic exit thesis. The wrong fit is an early-stage company; GIC’s check size and diligence process are not designed for seed or Series A. The right entry path is through global investment banks active in healthcare M&A and capital markets, through tier-one US and European Series A and Series B investors who frequently bring GIC into Series C and later rounds, through Singapore-based institutional relationships, and through warm introductions from GIC’s existing portfolio CEOs and from senior banking and advisory networks. Cold inbound to a sovereign wealth fund of this scale is generally not productive. When pitching, lead with the institutional-grade financial picture, the global market opportunity, and the operational discipline that justifies large-scale capital deployment, then connect to the strategic thesis on Asia or specific geographies relevant to GIC’s broader portfolio. Caveats: GIC’s diligence process is rigorous and slow, and the firm’s institutional posture means founders should expect full information rights, governance representation, and a long-term investor relationship. The firm is also not positioned as an AI-native specialist, with healthcare investments emphasizing therapeutics, infrastructure, and large-scale digital health rather than research-stage AI. Use GIC when you are running a globally significant healthcare business at growth stage and need sovereign-grade capital with multi-decade horizon and Asian institutional credibility.